Fibrocell Science Inc (NASDAQ:FCSC) Short Interest Update
Fibrocell Science Inc (NASDAQ:FCSC) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 651,800 shares, a drop of 11.0% from the July 31st total of 732,400 shares. Currently, 8.1% of the company’s stock are short sold. Based on an average daily trading volume, of 100,600 shares, the days-to-cover ratio is presently 6.5 days.
A number of hedge funds have recently bought and sold shares of the stock. Morgan Stanley lifted its stake in Fibrocell Science by 13.2% during the second quarter. Morgan Stanley now owns 59,900 shares of the company’s stock worth $114,000 after purchasing an additional 7,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Fibrocell Science by 140.6% during the second quarter. Vanguard Group Inc. now owns 394,456 shares of the company’s stock worth $749,000 after purchasing an additional 230,522 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Fibrocell Science by 38.0% during the second quarter. Renaissance Technologies LLC now owns 740,454 shares of the company’s stock worth $1,407,000 after purchasing an additional 204,015 shares during the last quarter. Bank of Montreal Can purchased a new stake in Fibrocell Science during the second quarter worth approximately $71,000. Finally, Apis Capital Advisors LLC purchased a new stake in Fibrocell Science during the first quarter worth approximately $48,000. Hedge funds and other institutional investors own 32.92% of the company’s stock.
FCSC has been the subject of several recent research reports. HC Wainwright cut Fibrocell Science from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Friday. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “strong-buy” rating and set a $2.25 price objective for the company in a research note on Wednesday, August 21st. Finally, ValuEngine upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $1.30. The company had revenue of $21.79 million during the quarter. Equities analysts predict that Fibrocell Science will post 0.1 earnings per share for the current fiscal year.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Recommended Story: Stochastic Momentum Index (SMI)
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.